



ImpediMed Limited

Suite 31C, 12-18 Tryon Rd  
Lindfield NSW 2070  
Australia

E: [investorrelations@impedimed.com](mailto:investorrelations@impedimed.com)

W: [impedimed.com](http://impedimed.com)

10 June 2026

Companies Announcements Office  
Australian Securities Exchange

## Oversubscribed Share Purchase Plan successfully completed

### Highlights

- The oversubscribed Share Purchase Plan closed on Friday, 5 June 2026, raising \$2.1 million and following a \$13.2 million institutional placement.
- Approximately \$1.4 million in oversubscriptions has been received, with the Board expecting to accept up to an additional \$0.1 million above the initial \$2.0 million target.
- Participants in the SPP will receive one Attaching Option per SPP Share subscribed for, and a further Follow-on Option that may be exercised following the valid exercise of the first attaching option.

---

ImpediMed Limited (ASX: IPD) (**ImpediMed** or the **Company**) is pleased to announce the successful completion of its Share Purchase Plan (**SPP**), announced on Monday, 4 May 2026. The SPP closed on Friday, 5 June 2026, following a \$13.2 million institutional placement (**Placement**).

The SPP provided eligible shareholders in Australia and New Zealand the opportunity to apply for up to \$100,000 of new fully paid ordinary shares in ImpediMed (**SPP Shares**) without incurring brokerage, commissions, or other transaction costs.

The SPP was oversubscribed, with applications totalling \$3.5 million, exceeding the initial target of A\$2.0 million. As announced on 12 May 2026, the Board may, at its discretion, accept oversubscriptions of up to an additional 100 million SPP Shares. Accordingly, the Board has resolved to accept oversubscriptions of up to an additional A\$0.1 million, bringing the total capital raised under the SPP to A\$2.1 million and total number of SPP Shares to be issued at 300 million. A scale-back on a pro rata basis will be applied.

The issue price under the SPP was determined in accordance with the terms of the Prospectus and set at \$0.007 per SPP Share, representing a 2.5% discount to the 5-day VWAP of shares

For personal use only

# impedimed<sup>®</sup>

traded on the ASX up to and including the SPP closing date. It is expected 300 million SPP Shares will be issued at this price, and SPP participants will also receive one Attaching option and one Follow-on Option for each SPP share issued.

The issue of SPP Shares and Tranche 2 of the Placement, as well as the issue of options under both the SPP and the Placement, will be subject to shareholder approval at a general meeting scheduled for 11 June 2026 (**EGM**). Following shareholder approval, the Company will apply for quotation of all shares and options issued under the SPP and the Placement.

The SPP Shares and all Attaching Options and Follow-on Options are expected to be issued on Monday, 15 June 2026 and to commence trading on the ASX on Tuesday, 16 June 2026. Holding statements are expected to be dispatched to successful applicants on Tuesday, 16 June 2026.

Chair of the Board Christine Emmanuel-Donnelly said "We are very pleased with the strong response to the Share Purchase Plan, which reflects the continued confidence and support of our shareholders. On behalf of the Board, I would like to sincerely thank our investors for their participation and commitment to the Company. This level of support is greatly appreciated and positions us well for the next phase of our growth strategy."

## **Extraordinary General Meeting**

The EGM will take place on Thursday, 11 June 2026 commencing at 11:00am (AEST). Shareholders are encouraged to review the Notice of Meeting available on the Company's website at <https://investors.impedimed.com/announcements/7535023>. Shareholders may attend the meeting in person at the offices of Clifford Chance, Level 24 Brookfield Place, 10 Carrington Street, Sydney NSW 2000, or online by entering the following link into a web browser: <https://meetings.openbriefing.com/IPDEGM26>. Further information is provided in the online meeting guide, also available on the Company's website at <https://investors.impedimed.com/announcements/7535027>.

For more information, contact Investor Relations at [investorrelations@impedimed.com](mailto:investorrelations@impedimed.com).

**Approved for release by the Board of ImpediMed Limited**

# impedimed®

## About ImpediMed

Headquartered in Sydney, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health. ImpediMed produces the SOZO® Digital Health Platform, which is FDA-cleared, CE-marked, and ARTG-listed for multiple indications, including lymphoedema, heart failure, and protein calorie malnutrition and sold in select markets globally.

In March 2024, the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) for Survivorship continue to reference bioimpedance spectroscopy as the recommended objective tool to screen at-risk cancer patients for early signs of lymphoedema. With the SOZO Digital Health Platform and L-Dex®, ImpediMed is the only company to offer FDA-cleared technology that uses bioimpedance spectroscopy for the clinical assessment of lymphoedema. The connected digital health platform and large, attractive cancer-related lymphoedema market present an opportunity for continued strong growth through ImpediMed's SaaS subscription-based business.

For more information, visit [www.impedimed.com](http://www.impedimed.com).

## Forward looking statements

This announcement contains or may contain forward-looking statements that are based on ImpediMed Limited (ImpediMed) management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position. Any forward-looking statements, including projections, guidance on future revenues, earnings and estimates, are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance.

While management has prepared this information based on its current knowledge and understanding and in good faith, there are risks and uncertainties involved which could cause actual results to differ from projections. You should not place undue reliance on forward-looking statements which speak only as of the date when made. Except as required by law, ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements and no representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including ImpediMed Limited).

**impedimed<sup>®</sup>**

For personal use only